Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.5991
-0.12-16.68%
At close: -
$0.6300
0.035.16%
After Hours: Apr 4, 7:13 PM EDT
Comments
Loading...
Context Therapeutics Analyst Ratings and Price Targets | NASDAQ:CNTX | Benzinga
Context Therapeutics Inc has a consensus price target of $6.5 based on the ratings of 5 analysts. The high is $10 issued by Maxim Group on May 9, 2024. The low is $4 issued by JMP Securities on January 8, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., D. Boral Capital, and D. Boral Capital on March 21, 2025, March 21, 2025, and January 15, 2025, respectively. With an average price target of $7.67 between HC Wainwright & Co., D. Boral Capital, and D. Boral Capital, there's an implied 1116.93% upside for Context Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
D. Boral Capital
JMP Securities
Piper Sandler
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Context Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/21/2025 | Buy Now | 693.65% | HC Wainwright & Co. | Emily Bodnar38% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2025 | Buy Now | 1328.57% | D. Boral Capital | Jason Kolbert43% | $9 → $9 | Maintains | Buy | Get Alert |
| 01/15/2025 | Buy Now | 1328.57% | D. Boral Capital | Jason Kolbert43% | $9 → $9 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | 534.92% | JMP Securities | Silvan Tuerkcan44% | → $4 | Initiates | → Market Outperform | Get Alert |
| 11/25/2024 | Buy Now | 1328.57% | D. Boral Capital | Jason Kolbert43% | → $9 | Initiates | → Buy | Get Alert |
| 09/23/2024 | Buy Now | 852.38% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 852.38% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2024 | Buy Now | 693.65% | HC Wainwright & Co. | Emily Bodnar38% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 614.29% | Piper Sandler | Joseph Catanzaro41% | → $4.5 | Initiates | → Overweight | Get Alert |
| 05/09/2024 | Buy Now | 693.65% | HC Wainwright & Co. | Emily Bodnar38% | $4 → $5 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 1487.3% | Maxim Group | Jason McCarthy41% | $4 → $10 | Maintains | Buy | Get Alert |
| 03/21/2024 | Buy Now | 534.92% | HC Wainwright & Co. | Emily Bodnar38% | $5 → $4 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | 693.65% | HC Wainwright & Co. | Emily Bodnar38% | → $5 | Upgrade | Neutral → Buy | Get Alert |
| 09/11/2023 | Buy Now | 534.92% | Maxim Group | Jason McCarthy41% | → $4 | Initiates | → Buy | Get Alert |
| 06/06/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | — | Reiterates | → Neutral | Get Alert |
| 03/23/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | — | Downgrade | Buy → Neutral | Get Alert |
| 02/07/2023 | Buy Now | 534.92% | HC Wainwright & Co. | Emily Bodnar38% | → $4 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Context Therapeutics (CNTX) stock?
The latest price target for Context Therapeutics (NASDAQ:CNTX) was reported by HC Wainwright & Co. on March 21, 2025. The analyst firm set a price target for $5.00 expecting CNTX to rise to within 12 months (a possible 693.65% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Context Therapeutics (CNTX)?
The latest analyst rating for Context Therapeutics (NASDAQ:CNTX) was provided by HC Wainwright & Co., and Context Therapeutics reiterated their buy rating.
When was the last upgrade for Context Therapeutics (CNTX)?
The last upgrade for Context Therapeutics Inc happened on November 1, 2023 when HC Wainwright & Co. raised their price target to $5. HC Wainwright & Co. previously had a neutral for Context Therapeutics Inc.
When was the last downgrade for Context Therapeutics (CNTX)?
The last downgrade for Context Therapeutics Inc happened on March 23, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Context Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Context Therapeutics (CNTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Context Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Context Therapeutics was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.
Is the Analyst Rating Context Therapeutics (CNTX) correct?
While ratings are subjective and will change, the latest Context Therapeutics (CNTX) rating was a reiterated with a price target of $5.00 to $5.00. The current price Context Therapeutics (CNTX) is trading at is $0.63, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.